Thu Sep 12 05:50:56 UTC 2024: ## Ionis Pharmaceuticals (IONS) Receives Upgraded Earnings Forecast, Stock Sees Increased Institutional Interest
**San Diego, CA – September 12, 2024** – Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) has seen a boost in its stock value following an upgraded earnings forecast by Leerink Partners analysts. The analysts have increased their FY2028 earnings per share (EPS) estimates for Ionis, projecting a $2.77 per share profit for the year, up from their previous estimate of $2.71. Leerink Partners maintains a “Strong-Buy” rating on the stock.
This positive outlook comes on the heels of a strong second-quarter earnings report for Ionis. The company reported ($0.45) EPS for the quarter, exceeding analysts’ consensus estimates of ($0.92) by $0.47. Revenue for the quarter reached $225.00 million, surpassing analyst expectations of $152.35 million.
While Ionis continues to operate with negative net margins and a negative return on equity, its revenue saw a 19.7% year-over-year increase. This positive trend has attracted the attention of institutional investors, with several making significant purchases of IONS stock during the past quarters.
Notable among these is Pingora Partners LLC, who acquired a new stake in Ionis Pharmaceuticals during the fourth quarter valued at approximately $25,000. Other investors include Mather Group LLC, nVerses Capital LLC, Itau Unibanco Holding S.A., and Sunbelt Securities Inc., all of whom made significant new investments in Ionis during the first or second quarters. Institutional investors now own a substantial 93.86% of the company’s stock.
Despite this positive news, recent insider transactions show some selling activity. Director Joseph Klein III sold 12,000 shares of the firm’s stock on July 16th, and EVP Richard S. Geary sold 2,430 shares on August 5th. However, it is important to note that insiders still own 2.71% of the company’s stock.
Ionis Pharmaceuticals, a leading developer of RNA-targeted therapeutics, continues to focus on delivering innovative treatments for debilitating diseases. The company’s portfolio includes SPINRAZA for spinal muscular atrophy (SMA), TEGSEDI for hereditary transthyretin amyloidosis, and WAYLIVRA for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.
The recent positive developments in Ionis’s financial performance and the increased institutional interest in the company suggest a positive outlook for the future. With ongoing research and development efforts, Ionis is well-positioned to continue delivering life-changing therapies and generate significant shareholder value.
First Piper 